Publications by authors named "Margo Zaval"

Claim this Profile
H
HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer.
Devra Olson, Janelle Taylor, Kelsi Willis, Kelly Hensley, Sean Allred, Margo Zaval

Cancer Res Commun· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific Conjugation.
Joseph Z Hamilton, Thomas A Pires, Jamie A Mitchell, Julia H Cochran, Kim K Emmerton, Margo Zaval

ChemMedChem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Novel Antibody-Camptothecin Conjugates.
Ryan D Lyski, Lauren B Bou, Uland Y Lau, David W Meyer, Julia H Cochran, Margo C Zaval

Mol Cancer Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationships of tubulysin analogues.
Joel R Courter, Joseph Z Hamilton, Nathaniel R Hendrick, Margo Zaval, Andrew B Waight

Bioorg Med Chem Lett· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody-Drug Conjugates.
Christopher S Neumann, Kathleen C Olivas, Martha E Anderson, Julia H Cochran, Steven Jin, Margo C Zaval

Mol Cancer Ther· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins.
Uland Y Lau, Lauren T Benoit, Nicole S Stevens, Kim K Emmerton, Margo Zaval

Mol Pharm· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis